Uncovering the specialized immune cells that fight COVID-19

Sep 4, 2024

uncovering-the-special-1

Mass cytometry analysis of B cells reveals distinct groups of activated and resting memory B cell populations. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-50997-4

Vaccines work by equipping our immune systems to fight an invading virus. When we get vaccinated against COVID-19, specialized immune cells known as B cells learn to recognize the virus. If we subsequently get infected with COVID, these B cells will quickly manufacture antibodies to attack and destroy the virus. However, because the mRNA vaccines developed for COVID-19 are so new, researchers did not know exactly which B cells were called into action.

Now, in a study published in Nature Communications, a team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination.

“Several different types of B cells can be activated after vaccination, but it was not clear which B cells responded to the COVID-19 mRNA vaccine,” says lead author David Priest. “We found that blood from people who were vaccinated against COVID-19 contained activated atypical B cells. These B cells are the main responders to the vaccine because they are highly correlated with the serum antibody response against the COVID-19 virus.”

The team used a method called mass cytometry to examine and identify individual cells within the two known groups of B cells. These groups are classical B cells, which are common in human blood, and non-classical B cells. The newly discovered activated atypical cells fall into the non-classical group. The team also found these cells in the blood of patients who were infected with COVID-19.

“Activated atypical B cells provide a new way to assess how well people respond to COVID-19 vaccination. They also give us a new understanding of the underlying biology of mRNA vaccination,” explains senior author James Wing. “Now that we know these B cells are the primary responders to mRNA vaccines, we can work toward targeting them in future vaccine designs.”

With the help of this study, researchers may be able to develop improved updates to current COVID-19 vaccines as well as better candidate vaccines to help prevent future pandemics.

Source:
https://medicalxpress.com/news/2024-09-uncovering-specialized-immune-cells-covid.html
GMP mRNA
Check out our mRNA service to expedite your vaccine research
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

AAV Packaging Services

We have developed a series of proprietary technologies that greatly improve AAV production outcomes including titer, purity, potency, and consistency.

READ MORE

Off-the-Shelf AAV Products

We offer a library of carefully designed and pre-stocked AAV vectors for a wide variety of experimental needs.

READ MORE